Replies to post #132197 on Biotech Values

[Anslau]

Sanofi Discontinues Generic Lovenox; Momenta Rises 3.1%
2011-12-01 15:05:33.872 GMT


By Clyde Eltzroth and Sasha Damouni
    Dec. 1 (Bloomberg) -- Sanofi said it’s discontinuing
authorized generic form of Lovenox, according to Nov. 30 letter.
 * Sanofi said action is in response to “changing market
   conditions,” “limited to this product only”
 * NOTE: Oct. 28 MNTA got preliminary injunction vs Amphastar,
   Watson; Link: {NSN LTSNBA6S9728 <go>}
 * Monness Crespi Hardt analyst Avik Roy raised MNTA PT to $23
   from $22 earlier, says MNTA market share will
   “substantially increase,” “pricing pressure decrease” as
   a result of SNY discontinuing generic Lovenox
 * Sanofi didn’t return request for comment to Bloomberg First
   Word
 * Momenta up as much as 3.1%

Link to Company News:{MNTA US <Equity> CN <GO>}
Link to Company News:{NOVN VX <Equity> CN <GO>}
Link to Company News:{SAN FP <Equity> CN <GO>}
Link to Company News:{WPI US <Equity> CN <GO>}
Link to Company News:{253123Z US <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the reporter on this story:
Clyde Eltzroth in New York at [phone] or
[e-mail]

To contact the editor responsible for this story:
Brad Skillman at [phone] or
[e-mail]